ABSTRACT: The ρ 1 GABA C receptor is a ligand-gated chloride ion channel that shows promise as a therapeutic target for myopia, sleep disorders, memory and learning facilitation, and anxietyrelated disorders. As such, there is a need for molecular probes to understand the role GABA C receptors play in physiological and pathological processes. To date, no labeled (either radioactive or fluorescent) GABA C selective ligand has been developed that can act as a marker for GABA C receptor visualization and localization studies. Herein, we report a series of fluorescent ligands containing different-sized linkers and fluorophores based around (S)-4-ACPBPA [(4-aminocyclopenten-1-yl)-butylphosphinic acid], a selective GABA C antagonist. One of these conjugates, (S)-4-ACPBPA-C5-BODIPY (13), displayed moderate potency (IC 50 = 58.61 μM) and selectivity (>100 times) for ρ 1 over α 1 β 2 γ 2L GABA A receptors. These conjugates are novel lead agents for the development of more potent and selective fluorescent probes for studying the localization and function of GABA C receptors in living cells.
γ-Aminobutyric acid 1 [GABA (Figure 1) ] is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS) and is essential for the overall balance between neuronal excitation and inhibition.
1,2 GABA released from GABAergic axon terminals influences neurons via GABA A , GABA B , and GABA C (GABAρ) receptors. These receptors are grouped on the basis of their subunit composition, gating properties, and pharmacological profiles. GABA A and GABA C receptors are ligand-gated chloride ion channels that mediate fast synaptic inhibition when activated by GABA, 1 whereas GABA B receptors are G-protein-coupled receptors that mediate slow, longer-lasting synaptic inhibition by increasing potassium and decreasing calcium conductances when activated by GABA. 3 Ionotropic GABA A receptors are transmembrane protein complexes composed of five heteropentameric subunits. To date, 16 human GABA A receptor subunits have been identified and classified as α (α 1 −α 6 ), β (β 1 −β 3 ), γ (γ 1 −γ 3 ), δ, ε, π, and θ. 4 In contrast, ionotropic GABA C receptors have pharmacology, physiology, and subunit compositions distinct from those of GABA A . 5, 6 In mammals, GABA C receptors are composed of ρ subunits (ρ 1 −ρ 3 ), forming homopentameric assemblies of five ρ subunits (ρ 1 , ρ 2 , or ρ 3 subunits) or pseudoheteropentameric complexes comprising different ρ subunits (a combination of ρ 1 and ρ 2 or ρ 2 and ρ 3 subunits). 5, 7, 8 . 10 This clearly indicates that the GABA binding sites of GABA C and GABA A receptors are not identical.
GABA A receptors are widely distributed in the CNS, 1 whereas GABA C receptors are mainly expressed in the superior colliculus, 11 cerebellum, 12 lateral amyglada, 13 hippocampus (strong ρ 2 subunit expression), 14 and, most prominently, the retina (strong ρ 1 subunit expression). 7 Various studies show that GABA C receptors are potential therapeutic targets for myopia, sleep disorders, managing memory-related disorders, and peripheral antinociception. 5, 13 However, understanding the role of GABA C receptors and information about the processes triggered by ligand−receptor interactions in living cells are still limited because of the lack of pharmacological tools.
Fluorescent ligands have proven to be useful tools offering a wealth of information about the mapping or identification of ligand binding sites, 15, 16 the mechanism of ligand binding, 17 the physical nature of the binding pocket, the movement and internalization of receptors in living cells, 18 and the localization as well as visualization of the labeled receptors. 19 Biotinylated probes are useful for the isolation and purification of target proteins of the receptor fragment for crystallization and X-ray studies of the particular receptor-binding site, 20 the localization and visualization of the receptor by using antibodies, 21 and the study of ligand−protein interactions in living cells. 22 In addition, fluorescent and biotinylated probes represent a faster, safer, and less expensive alternative to radioligands in receptor studies, circumventing several drawbacks associated with radioligand studies such as health and safety concerns and the need for a large number of cells with strong receptor expression. 23 Thus, the identification of fluorescent or biotinylated ligands for GABA C receptors is of great interest. The development of these tagged ligands usually starts with the selection of a potent and selective pharmacophore, which is then conjugated with the desired tag through an appropriate linker.
To date, only a few fluorescent and biotinylated GABA B receptor antagonist ligands have been reported, 24 and Nacylation of the amino moiety of muscimol (2), a widely used GABA A agonist that it is also a potent partial agonist at human ρ 1 GABA C receptors with fluorophores, has been shown to result in ligands that bind to the GABA A receptors. 25 Vu et al. presented evidence that muscimol linked through a 6-aminohexanoyl chain to biotin (muscimol-biotin; EC 50 = 20 μM) and BODIPY (muscimol-BODIPY) retained substantial agonist activity compared to muscimol (2; EC 50 = 2 μM) at GABA C receptors, 26 indicating a steric tolerance in the region around the ligand's amine binding site of the GABA C receptor. To the best of our knowledge, no selective fluorescent ligand for GABA C receptors has been described in the literature. Therefore, we envisioned that incorporating fluorophores or the versatile biotin moiety into selective GABA C ligands could lead to selective probes. Herein, we report the design, synthesis, and pharmacological evaluation of the selective fluorescent and biotinylated probes for ρ 1 GABA C receptors.
We selected two of our previously reported selective and potent GABA C antagonists, (S)-4-ACPBPA 6 and (R)-4-ACPBPA 7 (Figure 1 ), for the design of the fluorescent GABA C antagonists. 9 Both were synthesized according to our previously published protocol. 9 The length of the spacer chain is known to significantly impact the affinity of ligand− fluorophore conjugates for the receptors; therefore, we chose a linker size that varied from 0 to 10 carbons to introduce molecular flexibility into the conjugated fluorescent ligand. We incorporated fluorescent groups with relatively small to large molecular volumes to study the effect of perturbation on receptor affinity. We used the fluorophores NMA (Nmethylanthranilic acid), BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene), and NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl) chloride, which are known to have different excitation wavelengths and distinctive properties, to diversify fluorescence experiments. BODIPY has been extensively utilized for the development of fluorescent probes because of its distinctive and useful features, including hydrophobicity, photochemical stability, insensitivity to changes in experimental conditions, efficient uptake into cell membranes, and high extinction coefficient and fluorescence quantum yield. 27 Initially, we synthesized fluorescent probes using the potent and selective GABA C antagonist (S)-4-ACPBPA 6 by linking the small fluorophore NMA through linkers of various sizes. The synthesis of (S)-4-ACPBPA-NMA-and (R)-4-ACPBPA-C5-NMA-conjugated target compounds (S)-11a−g and (R)-11d is depicted in Scheme 1. N-Succinimidyl esters 9a−g were prepared by protection of the amine function of the amino acids with a tert-butyloxycarbonyl group (Boc), followed by activation of the acid function of the amino acids with an Nhydroxysuccinimide (NHS) (see the Supporting Information for the experimental details). The activated N-succinimidyl esters 9a−g were further reacted with the GABA C antagonist (S)-4-ACPBPA 6 in an aqueous NaHCO 3 solution at room temperature, and subsequent removal of the Boc group using TFA in CH 2 Cl 2 to afford compounds 10a−g in moderate to good yields. Target compounds (S)-11a−g were obtained by amide coupling of compounds (S)-10a−g with NHS-activated fluorophore NMA (NMA N-succinimidyl ester) in an aqueous NaHCO 3 solution at room temperature. (R)-10d was obtained from 9d as described above for the preparation of (S)-10d. (R)-11d was synthesized by reaction of (R)-4-ACPBPA 7 with the previously prepared ester (R)-10d under basic conditions at room temperature.
Fluorescent compounds 12 and 13 containing the NBD and BODIPY moieties were prepared as depicted in Scheme 2. Condensation of 7-nitrobenz-2-oxa-1,3-diazol-4-yl chloride (NBD chloride) with (S)-10d in a K 2 CO 3 /DMF mixture at room temperature afforded target compound 12 in moderate yield. The synthesis of BODIPY N-succinimidyl ester (see the Supporting Information for the experimental details) was achieved in two steps according to a previously described method. 28 Compound 13 was obtained in moderate yield by reaction of BODIPY succinimidyl ester and the primary amine of (S)-10d in a DIPEA/DMF mixture at room temperature.
Biotinylated conjugates 15 and 16 were prepared according to Scheme 3. Formation of an amide bond between biotin Nsuccinimidyl ester 14 and the corresponding primary amine of (S)-4-ACPBPA 6 and compound (S)-10d in a DIPEA/DMF mixture at room temperature afforded biotinylated conjugates 15 and 16, respectively.
We examined the functional characterization of fluorescent and biotinylated probes on human recombinant GABA receptors expressed in Xenopus oocytes using the two-electrode voltage clamp method (Table 1) . 9 ,10 All 12 probes [(S)-11a−g, (R)-11d, 12, 13, 15, and 16] were evaluated for activity alone and in the presence of GABA on GABA A (α 1 β 2 γ 2L ), and ρ 1 GABA C receptors to determine whether they behave as agonists, antagonists, or modulators. During the initial pharmacological screening, we found that stable and reproducible levels of inhibition of GABA (1 μM) at ρ 1 GABA C receptors were reached only after a 5 min preincubation with compounds (S)-11a−g and (R)-11d (see the Supporting Information for details). The preincubation needed for some of the compounds for reaching stable and reproducible levels of inhibition of GABA may be due to a molecule's size and lipophilicity needing additional time to diffuse into the binding site. In the (S)-4-ACPBPA-NMA series where the NMA group was attached to the primary amine of the ligand through an aminoalkanoyl chain, we observed that compounds with a chain length of fewer than five carbons [compounds (S)-11a−c] exhibited weak antagonist activity, compared to compound (S)-11d with a five-carbon chain. The activity for compounds (S)-11e−g decreased with an increasing chain length. These compounds had a chain length of 6−10 carbons, indicating that a linker of five carbons is optimal. The decrease in activity for compounds (S)-11a and (S)-11b (spacer size of fewer than four carbons) could be explained by the relative rigidity caused by the amido-containing chain with the ligand moiety at the binding site. With spacer sizes of more than six carbons, the fluorescent tag may occupy a less favorable area, resulting in a decrease in inhibitory activity.
The optimal chain length of the linker is important for the introduction of molecular flexibility for more convenient positioning of the ligand into the receptor. After optimization of the chain length for fluorescent probes, we linked (R)-4-ACPBPA through a 6-aminohexanoyl chain to NMA [(R)-11d] and evaluated its activity on ρ 1 GABA C receptors. (R)-4-ACPBPA 7 is 12-fold less potent than (S)-4-ACPBPA 6 at the ρ 1 GABA C receptor (Figure 1) . 9 However, (R)-4-ACPBPA-C5-NMA (R)-11d exhibited activity almost equal to that of (S)-4-ACPBPA-C5-NMA (S)-11d, indicating N-acylation of the amine removed the differential activity of enantiomers.
We also evaluated NBD and BODIPY (12 and 13, respectively) containing probes on both ρ 1 GABA C and α 1 β 2 γ 2L GABA A receptors with and without preincubation (Table 1) activity was slightly improved (IC 50 = 193.27 μM) with a 5 min preincubation at ρ 1 GABA C receptors. (S)-4-ACPBPA-C5-BODIPY 13 displayed moderate and improved potency (IC 50 = 58.61 μM with preincubation, and IC 50 = 103.14 μM without preincubation) at ρ 1 GABA C receptors. The increase in activity for (S)-4-ACPBPA-C5-BODIPY 13 but not for (S)-4-ACPBPA-C5-NMA (S)-11d and (S)-4-ACPBPA-C5-NBD 12 indicates that bulkier fluorophores linked by a 6-aminohexanoyl chain are more favorable for activity. These results confirmed the prediction of molecular modeling studies that the large hydrophobic region of the receptor is located adjacent to the binding site of the basic amino group of (S)-4-ACPBPA. As expected, probes (S)-11d, (R)-11d, 12, and 13 were found to be inactive (at 300 μM) at α 1 β 2 γ 2L GABA A receptors.
We also evaluated biotinylated probes of (S)-4-ACPBPA (compounds 15 and 16) on the ρ 1 GABA C receptor. Biotincoupled probes are suitable for subcellular localization of receptors because biotin forms a tight complex with strept(avidin), 21 which can be visualized by confocal microscopy using antibodies. Direct attachment of the biotin group to (S)-4-ACPBPA was deleterious for activity, (compound 15 was inactive at 300 μM). However, a linker length of five carbons (compound 16) is sufficient to restore moderate activity (IC 50 = 76.54 μM with preincubation, and IC 50 = 147.92 μM without preincubation) at ρ 1 GABA C receptors. These findings represent the first demonstration of electrophysiological activity by N-acyl derivatives of selective antagonists (S)-4-ACPBPA 6 and (R)-4-ACPBPA 7.
To identify structural determinants for the observed activity for the ρ 1 GABA C receptor, we flexibly docked the structures of (Figure 2A ). The binding affinity is largely ascribed to various electrostatic interactions, 29−31 including (i) a salt bridge interaction between the phosphinic acid and Arg104 and Arg158, 29, 30 (ii) hydrogen bond contacts of the amine of parent ligand or amide of probes with Glu196, 9 and (iii) hydrogen bond contacts with Thr244. 31 The docked model of compounds 6, (S)-11d, 12, 13, and 16 ( Figure 3 ) orients the (S)-4-ACPBPA moiety in the active site cavity of the ρ 1 GABA C receptor (shown with wire mesh) and a flexible spacer between the (S)-4-ACPBPA core and probe where the probe is pointing out of or residing in the noninteractive binding site of the receptors, which cannot be ruled out at this stage. The fluorophores or biotin tags are shown by molecular modeling studies to reside in a pocket away from the orthosteric site or extend into the extracellular space.
In conclusion, we have designed and synthesized for the first time fluorescent and biotinylated probes of selective antagonists for ρ 1 GABA C receptors. Pharmacological studies show that 12, 13, and 16 exhibit activity similar to that of the previously reported muscimol-based probes, 25, 26 with the added advantage that they are selective GABA C receptors. These results offer new knowledge regarding the binding site and receptor flexibility of GABA C receptors. The described fluorescent and biotinylated probes will be useful tools for localizing, visualizing, and studying the physiopathological processes of GABA C receptors. Further optimization of probes at amino and phosphinic acid moieties of (S)-4-ACPBPA, in vitro pharmacological evaluation, and fluorescent spectroscopic characterizations of all the probes are underway. 
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